Table 4.
Recipient, transplant, and clinical characteristics of cases of CMV disease
| Days Post HCT of Diagnosis | Graft | HCT Indication (Disease) | HCT Approach | Organ | D/R CMV Serostatus | Setting of CMV Disease | CMV Infection in 1st 100 days | Day of Post-HCT Death | Antiviral Resistance | Other Infectious Issues | Cause of Death |
|---|---|---|---|---|---|---|---|---|---|---|---|
| +34 | PBSC | Malignancy | CNI/mTORi | Colon | +/+ | Relapse | Day +31 | +38 | None | Relapse | |
| +84 | PBSC | Malignancy | CNI/mTORi | Stomach | +/+ | GVHD, relapse | Day +61 | +258 | Giardia | Relapse | |
| +29 | BM | Malignancy | CNI/mTORi | Lung | +/− | No events | Day +29 | Alive | None | N/A | |
| +212 | PBSC | Malignancy | CNI/mTORi | Colon | +/+ | GVHD | Day +49 | +372 | Ganciclovir (F412L,V812L in UL54 gene), foscarnet (V812L), cidofovir (F412L,V812L) | Paecilomyces sinusitis, VRE bacteremia, C. difficile colitis, BK-associated cystitis | GVHD with infectious complications |
| +254 | PBSC | Malignancy | TCD | Retina | +/+ | After 2nd HCT for graft failure | +897 | HHV6 reactivation, EBV elevation in blood, Klebsiella and E. coli UTIs, S. pneumoniae pneumonia | CNS relapse after 2nd HCT | ||
| +237 | PBSC | Malignancy | CNI/mTORi | Lung | +/− | Relapse, GVHD | Day +42 | +255 | Foscarnet (S585A in UL54 gene) | Aspergillus pneumonia | Secondary malignancy |
| +88 | PBSC | PID | Serotherapy | Lung | −/− | GVHD | Day +8 | +93 | Ganciclovir and foscarnet (A809V in UL54 gene) | Pyrenochaeta liver abscess, P. romeroi pneumonia, Klebsiella pneumonia and bacteremia | GVHD with infectious complications |
| #1: +22 #2: +85 | PBSC | Malignancy | CNI/mTORi | #1: Stomach #2: Colon | +/+ | #1: CMV just prior to GVHD #2: GVHD | Day +6 | +710 | #1: H. pylori gastritis, BK viremia, E. faecalis bacteremia, S. epidermidis bacteremia #2: Cholecystitis | Relapse | |
| +30 | PBSC | Malignancy | CNI/mTORi | Esophagus | +/+ | Relapse – 2nd HCT, then relapse again | Day +30 | +261 | HHV6 reactivation | Relapse | |
| +42 | PBSC | PID | PTCy | CNS | +/+ | GVHD | Day +43 | +83 | HHV6 reactivation, EBV elevation in blood, BKassociated cystitis, Cryptosporidium, S. aureus bacteremia, Pseudomonas bacteremia, disseminated Basidiomycetes infection | GVHD with infectious complications | |
| +237 | UCB | Aplastic Anemia | UCB | Lung | −/+ | GVHD | Day +22 | +416 | Ganciclovir (T503I,A809V in UL54 gene), foscarnet (A809V), cidofovir (T503I); CMV-CTLs | HHV6 reactivation, RSV LRTI, Cryptococcal sinusitis, MAC pneumonia, Aspergillus pneumonia | CMV pneumonitis |
| +15 | PBSC | Malignancy | Serotherapy | Colon | +/+ | GVHD | Day +21 | +83 | HSV viremia, EBV elevation in blood | Relapse | |
| +269 | PBSC | Malignancy | CNI/mTORi | Lung | +/+ | GVHD | Day +51 | Alive | Adenoviremia | N/A | |
| +108 | PBSC | PID | Serotherapy | Colon | +/+ | GVHD | Day +91 | +277 | Adenoviremia, EBV elevation in blood, BK-associated cystitis, Legionella peritonitis, Candida glabrata fungemia, VRE bacteremia, C. difficile colitis | GVHD with infectious complications | |
| +346 | PBSC | Malignancy | TCD | Colon | +/+ | Relapse – 2nd HCT, then GVHD | +595 | Disseminated Fusarium, S. mitis bacteremia, Klebsiella pneumoniae bacteremia | Relapse with infectious complications | ||
| +145 | PBSC | Malignancy | CNI/mTORi | Colon | +/+ | GVHD | Alive | BK-associated cystitis | |||
| +340 | PBSC | Malignancy | Serotherapy | Lung | −/+ | GVHD | Day +12 | +398 | Ganciclovir (C603W in UL97 gene), foscarnet (V715M in UL54 gene) | HHV6 reactivation, BK-associated cystitis | GVHD, uncontrolled CMV, TMA |
| #1: +48 #2: +385 | PBSC | PID | PTCy | #1: Stomach #2: Lungs | +/+ | #1 and 2: GVHD | Day +49 | +414 | BK-associated cystitis, primary EBV infection | GVHD with uncontrolled CMV | |
| +25 | PBSC | Hemoglobinopathy | Serotherapy | Colon | +/+ | No events | Day +19 | Alive | None | N/A |
Abbreviations: CMV, cytomegalovirus; HCT, hematopoietic cell transplantation; D/R, donor/recipient; PBSC, peripheral blood stem cell; BM, bone marrow; UCB, umbilical cord blood; PTCy, post-transplantation cyclophosphamide; TCD, ex vivo T-cell depletion; CNI/mTORi, calcineurin inhibitor or mammalian target of rapamycin inhibitor-based; GVHD, graft-versus-host disease; CMV-CTLs, CMV-specific cytotoxic T-lymphocytes; VRE, vancomycin resistant enterococcus; BK, BK virus; HHV6, human herpesvirus 6; EBV, Epstein-Barr virus; UTI, urinary tract infection; RSV, respiratory syncytial virus; LRTI, lower respiratory tract infection; MAC, M avium complex; HSV, herpes simplex virus; TMA, thrombotic microangiopathy; PID, primary immunodeficiency disease